6-chloro-N²-methyl-pyrimidine-2,4-diamine | 30117-05-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-chloro-N²-methyl-pyrimidine-2,4-diamine
• 英文别名: 6-chloro-2-N-methylpyrimidine-2,4-diamine
• CAS: 30117-05-6
• 化学式: C₅H₇ClN₄
• 分子量: 158.59
• InChiKey: BSFBUEBSAVYQQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS DANS LE TRAITEMENT DU CANCER
  申请人：MERCK PATENT GMBH

  公开号：WO2016128140A1

  公开（公告）日：2016-08-18

  Compounds of Formula I or II in which R1, X1 and X2 have the meanings indicated in claim 1, are MTH1 inhibitors and can be employed, inter alia, in the treatment of cancer.

  具有公式I或II的化合物，其中R1、X1和X2具有权利要求1中所示的含义，是MTH1抑制剂，可以用于治疗癌症。
• Benzimidazole-4-Carboxamide Derivatives, Their Preparation Methods, Pharmaceutical Compositions And Their Uses
  申请人：Luo Xianjin

  公开号：US20110269766A1

  公开（公告）日：2011-11-03

  The present invention relates to the benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses; wherein X represents monosubstituted or bissubstituted or polysubstitued C 1 -C 14 alkoxy, monosubstituted or bisubstituted or polysubstitued C 1 -C 14 alkyl, monosubstituted or bisubstituted or polysubstitued C 2 -C 14 alkenyl, monosubstituted or bisubstituted or polysubstitued C 6 -C 14 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom; Y represents hydrogen, monosubstituted or bisubstituted or polysubstitued C 1 -C 16 alkyl, monosubstituted or bisubstituted or polysubstitued C 6 -C 12 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom. The derivatives of the present invention have the functions of antiviral medicine.

  本发明涉及苯并咪唑-4-羧酰胺衍生物，其制备方法，药物组合物及其用途；其中X代表单取代或双取代或多取代的C1-C14烷氧基，单取代或双取代或多取代的C1-C14烷基，单取代或双取代或多取代的C2-C14烯基，单取代或双取代或多取代的C6-C14芳基，或单取代或双取代或多取代的含氮杂原子的5至6成员杂环基，或单取代或双取代或多取代的融合环基团；Y代表氢，单取代或双取代或多取代的C1-C16烷基，单取代或双取代或多取代的C6-C12芳基，或单取代或双取代或多取代的5至6成员杂环基，或单取代或双取代或多取代的融合环基团含氮杂原子。本发明的衍生物具有抗病毒药物功能。
• BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND THEIR USES
  申请人：Shanghai Jiao Tong University

  公开号：EP2386553A1

  公开（公告）日：2011-11-16

  The present invention relates to the benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses; wherein X represents monosubstituted or bissubstituted or polysubstitued C1-C14 alkoxy, monosubstituted or bisubstituted or polysubstitued C1-C14 alkyl, monosubstituted or bisubstituted or polysubstitued C2-C14 alkenyl, monosubstituted or bisubstituted or polysubstitued C6-C14 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom; Y represents hydrogen, monosubstituted or bisubstituted or polysubstitued C1-C16 alkyl, monosubstituted or bisubstituted or polysubstitued C6-C12 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom. The derivatives of the present invention have the functions of antiviral medicine.

  本发明涉及苯并咪唑-4-甲酰胺衍生物、其制备方法、药物组合物及其用途；其中 X 代表单取代或双取代或多取代的 C1-C14 烷氧基，单取代或双取代或多取代的 C1-C14 烷基，单取代或双取代或多取代的 C2-C14 烯基、单取代或双取代或多取代的 C6-C14 芳基，或单取代或双取代或多取代的 5 至 6 位杂环基团，或单取代或双取代或多取代的含氮杂原子的融合环基团；Y 代表氢、单取代或双取代或多取代的 C1-C16 烷基、单取代或双取代或多取代的 C6-C12 芳基、或单取代或双取代或多取代的 5 至 6 位杂环基团、或单取代或双取代或多取代的含氮杂原子的融合环基。本发明的衍生物具有抗病毒药物的功能。
• BENZIMIDAZOLE-4-CARBOXAMIDE DERIVATES, THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND THEIR USES
  申请人：Shanghai Jiao Tong University

  公开号：EP2963033A1

  公开（公告）日：2016-01-06

  The present invention relates to the benzimidazole-4-carboxamide derivatives of Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions and their uses. X represents thienyl monosubstituted by nitro or amino. unsubstituted thienyl; Y represents hydroxymethyl, hydroxyethyl, aminophenyl, hydroxyphenyl, C1-C6 alkylphenyl, phenyl monosubstituted by -F, -Cl, -Br or -I, phenyl bisubstituted by hydroxyl and carboxyl, hydroxyethyl bisubstituted by hydroxylmethyl or C1-C6 alkyl and monosubstituted phenyl, piperazinyl monosubstituted or bisubstituted or trisubstituted by C1-C6 alkyl or unsubstituted piperazinyl, pyridyl monosubstituted or bisubstituted or trisubstituted by C1-C6 alkyl or unsubstituted pyridyl, pyrazinyl monosubstituted or bisubstituted or unsubstituted by C1-C6 alkyl, piperazinyl monosubstituted or bisubstituted or trisubstituted by C1-C6 alkyl or unsubstituted piperazinyl, pyrrolyl monosubstituted or bisubstituted or trisubstituted by C1-C6 alkyl or unsubstituted pyrrolyl, thiazolyl monosubstituted by C1-C6 alkyl, pyrimidinyl monosubstituted or bisubstituted by C1-C6 alkyl or unsubstituted pyrimidinyl, pyrimidinyl monsubstituted by C1-C6 alkyl and bisubstituted by hydroxyl, pyrimidinyl monosubstituted by C1-C6 alkyl and bisubstituted or trisubstituted by -F, -Cl, -Br or -I, purinyl monosubstituted or bisubstituted by C1-C6 alkyl or unsubstituted purinyl, purinyl monosubstituted by hydroxyl.

  本发明涉及式（I）的苯并咪唑-4-甲酰胺衍生物或其药学上可接受的盐类、 药物组合物及其用途。 X 代表由硝基或氨基单取代的噻吩基； Y 代表羟甲基、羟乙基、氨基苯基、羟苯基、C1-C6 烷基苯基、由-F、-Cl、-Br 或-I 单取代的苯基、由羟基和羧基双取代的苯基、由羟甲基或 C1-C6 烷基双取代的羟乙基和单取代的苯基、由 C1-C6 烷基单取代或双取代或三取代的哌嗪基，或未取代的哌嗪基； 由 C1-C6 烷基单取代或双取代或三取代的吡啶基，或未取代的吡啶基； 由 C1-C6 烷基单取代或双取代或未取代的吡嗪基、由 C1-C6 烷基单取代或双取代或三取代的哌嗪基，或未取代的哌嗪基； 由 C1-C6 烷基单取代或双取代或三取代的吡咯基，或未取代的吡咯基； 由 C1-C6 烷基单取代的噻唑基； 由 C1-C6 烷基单取代或双取代的嘧啶基，或未取代的嘧啶基、由 C1-C6 烷基或未取代的嘧啶基、由 C1-C6 烷基取代的嘧啶基和由羟基取代的嘧啶基、由 C1-C6 烷基取代的嘧啶基和由-F、-Cl、-Br 或-I 取代的嘧啶基、由 C1-C6 烷基取代的嘌呤基或未取代的嘌呤基、由羟基取代的嘌呤基。
• PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER
  申请人：Merck Patent GmbH

  公开号：EP3256132A1

  公开（公告）日：2017-12-20